Paul Rennie “Let the data do the talking”. How many times has he said this? He seems confident.
Now we are all wondering, how many days until we get to truly measure the data on DMOAD. We get insight into the drug at 6months and a look through as to why we don’t need a commercially focussed CEO (yet). Rennie and the board may have had a suspicion our molecule just needs the time to prove itself as the stuff may very well sell itself (speculation).
At day 56, P value or .05 for pain and .017 for function on a sample size of 20 subjects compared to placebo. Some statisticians will maintain those results are too good to be true. We are about to find out more, either way.
Lets see.
research reports and media, page-3533
-
- There are more pages in this discussion • 864 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.015(6.82%) |
Mkt cap ! $78.70M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 22.0¢ | $17.5K | 75.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5642 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 45937 | 4 |
View Market Depth
| Last trade - 12.45pm 14/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |